Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: WeirdPro Randy who wrote (1069)	2/25/1998 7:30:00 PM
From: Pancho Villa	Read Replies (1) \| Respond to of 1359

>>I was amused by this statement and wondered if these same neurologists would abstain from the use of CerAxon (after it has been approved and becomes available)<< History is based in facts and not suppositions. Serious consideration of your statement requires drug approval which, as you well know, is by no means a fact. Also, I would like to point out once again that the results of the study as originally designed do not contradict my statement as the results showed no statistical significance. So I don't understand why you are so amused. Some [IMO not very professional] "After the fact" arbitrary cut of the population participating in the study was needed to show statistical significance. It is not unlikely for the FDA to require more testing. Cost efficiency is also part of the equation. This drug will not kill anyone but it is not free either. IMO the drug has a 50/50 chance of complete clearance. Pancho